Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
[HTML][HTML] Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?
…, P Ujhazy, C Zhou, K Goto, A Dowlati… - Journal of Thoracic …, 2016 - Elsevier
Small cell lung cancer (SCLC) is one of the four major histological types of lung cancer. The
incidence of SCLC in developed countries has declined in recent years, presumably …
incidence of SCLC in developed countries has declined in recent years, presumably …
[HTML][HTML] Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer
…, J Brahmer, JH Schiller, A Dowlati… - … England Journal of …, 2006 - Mass Medical Soc
Background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor,
has been shown to benefit patients with a variety of cancers. Methods Between July 2001 …
has been shown to benefit patients with a variety of cancers. Methods Between July 2001 …
[HTML][HTML] Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
…, AS Pappo, B Turpin, A Dowlati… - … England Journal of …, 2018 - Mass Medical Soc
Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a …
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a …
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data
N Levitan, A Dowlati, SC Remick, HI Tahsildar… - Medicine, 1999 - journals.lww.com
Abbreviations used in this article: DRG, Diagnostic Related Group; DVT, deep vein
thrombosis; HCFA, Health Care Financing Administration; ICD-9, International Classification of …
thrombosis; HCFA, Health Care Financing Administration; ICD-9, International Classification of …
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell …
AB Sandler, R Gray, J Brahmer, A Dowlati… - Journal of Clinical …, 2005 - ascopubs.org
LBA4 Background: The results of a randomized phase II trial of PC +/- bevacizumab (A)
suggested improved activity for the combination of PCA when compared to PC alone (Johnson …
suggested improved activity for the combination of PCA when compared to PC alone (Johnson …
Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology
…, A Chiang, TA D'Amico, C D'Avella, A Dowlati… - Journal of the National …, 2021 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Phase I trial of pazopanib in patients with advanced cancer
HI Hurwitz, A Dowlati, S Saini, S Savage, AB Suttle… - Clinical cancer …, 2009 - AACR
Purpose: The safety, pharmacokinetics, and clinical activity of pazopanib (GW786034), an
oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-…
oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-…
[PDF][PDF] Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis
…, JE Campbell, S Ribich, N Rekhtman, A Dowlati… - Cancer cell, 2017 - cell.com
Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost
every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled …
every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled …
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non–small cell lung cancer treated with chemotherapy …
A Dowlati, R Gray, AB Sandler, JH Schiller… - Clinical Cancer …, 2008 - AACR
Background: E4599 was a phase II/phase III trial, in which 878 patients with advanced non–small
cell lung cancer were randomized to carboplatin + paclitaxel (PC arm) or PC + …
cell lung cancer were randomized to carboplatin + paclitaxel (PC arm) or PC + …